Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis
…, JR Márquez, BB Scott, L Flint, HJF van Hoogstraten… - Gastroenterology, 2014 - Elsevier
… and Hubert van Hoogstraten were employees of Merck Sharp & Dohme Corp (a subsidiary
of Merck & Co, Inc) at the time the study was conducted and may hold stock options in the …
of Merck & Co, Inc) at the time the study was conducted and may hold stock options in the …
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a …
…, NMH Graham, H Van Hoogstraten… - Annals of the …, 2017 - ard.bmj.com
Objectives To compare efficacy and safety of sarilumab monotherapy with adalimumab
monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment …
monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment …
[PDF][PDF] Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study
…, S Fiore, P Rohane, H van Hoogstraten… - Arthritis & …, 2015 - Wiley Online Library
… Kivitz,3 Maria Rell-Bakalarska,4 Renata Martincova,5 Stefano Fiore,6 Patricia Rohane,6
Hubert van Hoogstraten,6 Anju Garg,6 Chunpeng Fan,6 Janet van Adelsberg,7 Steven P. …
Hubert van Hoogstraten,6 Anju Garg,6 Chunpeng Fan,6 Janet van Adelsberg,7 Steven P. …
[PDF][PDF] Sarilumab and nonbiologic disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor …
…, NMH Graham, H van Hoogstraten… - Arthritis & …, 2017 - Wiley Online Library
Objective To evaluate the efficacy and safety of sarilumab plus conventional synthetic
disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe …
disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe …
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis
HR van Buuren, HJF van Hoogstraten, T Terkivatan… - Journal of …, 2000 - Elsevier
Background/Aims: Traditionally, autoimmune hepatitis (AIH) and primary sclerosing cholangitis
(PSC) are regarded as separate disease entities. We report on a group of patients that …
(PSC) are regarded as separate disease entities. We report on a group of patients that …
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
…, Y Lin, C Pena-Rossi, H van Hoogstraten… - …, 2019 - academic.oup.com
Objective Safety and efficacy of mAbs blocking the IL-6 receptor have been established in
RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab …
RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab …
[HTML][HTML] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate …
…, NMH Graham, H van Hoogstraten… - Arthritis Research & …, 2016 - Springer
Background Sarilumab is a human monoclonal antibody directed against the alpha subunit
of the interleukin-6 receptor complex. In the MOBILITY phase III randomized controlled trial (…
of the interleukin-6 receptor complex. In the MOBILITY phase III randomized controlled trial (…
Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study
HJF van Hoogstraten, FP Vleggaar… - Official journal of the …, 2000 - journals.lww.com
OBJECTIVE: PSC has characteristics of an (auto) immune-mediated disease; however, few
studies have evaluated corticosteroid therapy for this disorder. METHODS: We performed an …
studies have evaluated corticosteroid therapy for this disorder. METHODS: We performed an …
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
…, C Fan, NMH Graham, H van Hoogstraten… - …, 2018 - academic.oup.com
Objectives To examine 2-year safety, efficacy and radiographic outcomes of sarilumab in adults
with RA and inadequate response to MTX (MTX-IR). Methods In the randomized, placebo…
with RA and inadequate response to MTX (MTX-IR). Methods In the randomized, placebo…
[HTML][HTML] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
…, Y Lin, EK Mangan, H van Hoogstraten… - Arthritis research & …, 2018 - Springer
Background The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated
that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor …
that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor …